Is It Time to Dump Your Shares of Pfizer?

The latest take on Pfizer Inc. (PFE) is raising eyebrows among investors. After a steep stock drop—around 50 % over recent years—Pfizer is facing serious headwinds. Its blockbuster vaccine‑era tailwinds have faded, and the upcoming “patent cliff” threatens revenue as key treatments lose exclusivity. Meanwhile, the company’s hefty dividend payout ratio is raising sustainability concerns. On the plus side, management is injecting fresh energy into R&D and pursuing acquisitions to diversify the pipeline. But for some shareholders, the question is simple: do you hold on and hope for a turnaround—or exit while you can? #Pfizer #StockWatch #PharmaPatents #InvestmentDecision #SlimScan #GrowthStocks #CANSLIM